In the study of Babour et al., BRAF mutated patients had a significant higher recurrence rate (77%) after three years of follow-up, than BRAF wild-type patients (54%; hazard ratio 1.8, p = 0.008) after CLND in a cohort of 124 stage IIIB/C melanoma patients. This evidence concerns the gene BRAF and melanoma.